Atara Biotherapeutics Inc’s recent filing unveils that its President and CEO Nguyen AnhCo unloaded Company’s shares for reported $38437.0 on Nov 17 ’25. In the deal valued at $13.19 per share,2,915 shares were sold. As a result of this transaction, Nguyen AnhCo now holds 64,974 shares worth roughly $0.89 million.
Then, Grant-Huerta Yanina sold 1,804 shares, generating $23,788 in total proceeds. Upon selling the shares at $13.19, the Chief Accounting Officer now owns 33,454 shares.
Before that, Nguyen AnhCo bought 3,346 shares. Atara Biotherapeutics Inc shares valued at $46,041 were divested by the Director at a price of $13.76 per share.
Mizuho downgraded its Atara Biotherapeutics Inc [ATRA] rating to a Neutral from a a Buy in a research note published on November 09, 2023; the price target was decreased to $1 from $31. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in early November from “a Buy” to “a Neutral”. Evercore ISI also remained covering ATRA and has decreased its forecast on November 09, 2023 with a “an In-line” recommendation from previously “an Outperform” rating. Citigroup revised its rating on July 20, 2022. It rated ATRA as “a Sell” which previously was an “a Neutral”.
Price Performance Review of ATRA
On Monday, Atara Biotherapeutics Inc [NASDAQ:ATRA] saw its stock fall -21.62% to $13.67. Over the last five days, the stock has lost -23.07%. Atara Biotherapeutics Inc shares have fallen nearly -18.87% since the year began. Nevertheless, the stocks have fallen -24.43% over the past one year.
How much short interest is there in Atara Biotherapeutics Inc?
A steep rise in short interest was recorded in Atara Biotherapeutics Inc stocks on 2025-12-15, dropping by 9921.0 shares to a total of 0.17 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 0.18 million shares. There was a decline of -5.95%, which implies that there is a negative sentiment for the stock.
